Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

Journal of Clinical Oncology

Volumn 31, Issue 25, 2013, Pages 3133-3140

  Iyer, Gopa ^a   Al Ahmadie, Hikmat ^a   Schultz, Nikolaus ^a   Hanrahan, Aphrothiti J ^a   Ostrovnaya, Irina ^a   Balar, Arjun V ^a   Kim, Philip H ^a   Lin, Oscar ^a   Weinhold, Nils ^a   Sander, Chris ^a   Zabor, Emily C ^a   Janakiraman, Manickam ^a   Garcia Grossman, Ilana R ^a   Heguy, Adriana ^a   Viale, Agnes ^a   Bochner, Bernard H ^a   Reuter, Victor E ^a,b   Bajorin, Dean F ^a,b   Solit, David B ^a,b   Milowsk, Matthew I ^c   Taylor, Barry S ^d   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; E2F3 PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; TRANSCRIPTION FACTOR E2F3;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER PATIENT; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; GENE SEQUENCE; GENOMICS; HUMAN; HUMAN CELL; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SANGER SEQUENCING; VALIDATION STUDY; BLADDER TUMOR; CANCER STAGING; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENETICS; MIDDLE AGED; MUTATION; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA COPY NUMBER VARIATIONS; E2F3 TRANSCRIPTION FACTOR; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; URINARY BLADDER NEOPLASMS;

EID: 84886561381     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.5740     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics. CA Cancer J Clin 60:277-300, 2010.
2. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009.
3. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010.
4. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010.
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
6. Janakiraman M, Vakiani E, Zeng Z, et al: Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70: 5901-5911, 2010.
7. Al-Ahmadie HA, Iyer G, Janakiraman M, et al: Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol 224:270-279, 2011.
8. Taylor BS, Barretina J, Socci ND, et al: Functional copy-number alterations in cancer. PLoS One 3:e3179, 2008.
9. Bolstad BM, Irizarry RA, Astrand M, et al: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193, 2003.
10. Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404, 2012.
11. Memorial Sloan-Kettering Cancer Center: cBioPortal for Cancer Genomics. http://www.cbioportal.Org.
12. Schulz WA: Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119: 1513-1518, 2006.
13. Kawanishi H, Takahashi T, Ito M, et al: High throughput comparative genomic hybridization array analysis of multifocal urothelial cancers. Cancer Sci 97:746-752, 2006.
14. Laé M, Couturier J, Oudard S, et al: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann Oncol 21:815-819, 2010.
15. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005.
16. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010.
17. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005.
18. Oliner JD, Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992.
19. McCann AH, Kirley A, Carney DN, et al: Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71:981-985, 1995.
20. Beroukhim R, Mermel CH, Porter D, et al: The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905, 2010.
21. Calzone L, Gelay A, Zinovyev A, et al: A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol 4:173, 2008.
22. Park KS, Liang MC, Raiser DM, et al: Characterization of the cell of origin for small cell lung cancer. Cell Cycle 10:2806-2815, 2011.
23. Krueger DA, Care MM, Holland K, et al: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801- 1811, 2010.
24. Iyer G, Hanrahan AJ, Milowsky MI, et al: Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221, 2012.
25. Hanrahan AJ, Schultz N, Westfal ML, et al: Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2:56-67, 2012.
26. Fry DW, Harvey PJ, Keller PR, et al: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427-1438, 2004.
27. Kojima K, Konopleva M, McQueen T, et al: Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcriptionindependent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108:993-1000, 2006.
28. Li M, Fang X, Baker DJ, et al: The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci U S A 107:14188-14193, 2010.
29. Wolff EM, Liang G, Jones PA: Mechanisms of Disease: Genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2:502-510, 2005.
30. She QB, Chandarlapaty S, Ye Q, et al: Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PloS One 3:e3065, 2008.
31. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757- 1765, 2008.
32. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005.
33. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012.